ST. LOUIS--(BUSINESS WIRE)--
Monsanto Company (NYSE: MON) today announced it has acquired Beeologics,
which researches and develops biological tools to provide targeted
control of pests and diseases. Terms of the deal were not disclosed.

Beeologics is focused on biological research. Current projects in its
pipeline – including a product candidate being developed to help protect
bee health – use a naturally-occurring process to provide targeted pest
and disease control.

The expertise Beeologics has developed will enable Monsanto to further
explore the use of biologicals broadly in agriculture. Monsanto will use
the base technology from Beeologics as a part of its continuing
discovery and development pipeline. Biological products will continue to
play an increasingly important role in supporting the sustainability of
many agricultural systems. Both companies expect that their combined
research could provide farmers with novel approaches to the challenges
they face.

Monsanto, which has proven expertise in managing a technology pipeline,
will support the Beeologics team and its Technology Advisory Board in
advancing its pipeline. Beeologics' work to promote bee health will
continue under Monsanto's ownership.

About Monsanto Company

Monsanto Company is a leading global provider of technology-based
solutions and agricultural products that improve farm productivity and
food quality. Monsanto remains focused on enabling both small-holder and
large-scale farmers to produce more from their land while conserving
more of our world's natural resources such as water and energy. To learn
more about our business and our commitments, please visit: www.monsanto.com.
Follow our business on Twitter® at www.twitter.com/MonsantoCo,
on the company blog, Beyond the Rows® at www.monsantoblog.com,
or subscribe to ourNews
Release RSS Feed
.

About Beeologics

Beeologics is an international firm dedicated to restoring bee health
and protecting the future of insect pollination. Through continuous
research, scientific innovation, and a focus on applicable solutions,
Beeologics is developing a line of products to specifically address the
long-term well being of the bees. With offices and laboratories in the
United States and Israel, Beeologics brings together some of the world's
most recognized scientists in its field to help achieve its mission. To
learn more about Beeologics, please visit: www.beeologics.com.

Cautionary Statements Regarding
Forward-Looking Information:

Certain statements contained in this release are "forward-looking
statements," such as statements concerning the company's anticipated
financial results, current and future product performance, regulatory
approvals, business and financial plans and other non-historical facts.
These statements are based on current expectations and currently
available information. However, since these statements are based on
factors that involve risks and uncertainties, the company's actual
performance and results may differ materially from those described or
implied by such forward-looking statements. Factors that could cause or
contribute to such differences include, among others: competition in
seeds, traits and agricultural chemicals and animal drugs; the company's
exposure to various contingencies, including those related to
intellectual property protection, regulatory submissions, regulatory
compliance and the speed with which approvals are received, and public
acceptance of biotechnology products; the success of the company's
research and development activities; the outcomes of major lawsuits;
developments related to foreign currencies and economies; successful
operation of recent acquisitions; fluctuations in commodity prices;
compliance with regulations affecting our manufacturing, labeling and
promotion; the accuracy of the company's estimates related to
distribution inventory levels; the company's ability to fund its
short-term financing needs and to obtain payment for the products that
it sells; the effect of weather conditions, natural disasters and
accidents on the agriculture and animal drug business or the company's
facilities; and other risks and factors detailed in the company's most
recent Form 10-K Report to the SEC. Undue reliance should not be placed
on these forward-looking statements, which are current only as of the
date of this release. The company disclaims any current intention or
obligation to update any forward-looking statements or any of the
factors that may affect actual results.